SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer. McCracken will be responsible for leading all commercial activities, driving revenue growth in new and
SOUTH SAN FRANCISCO, Calif. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor
SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 12, 2019 , under
Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to $113.0 million Including equity offering, ending cash of $95.4 million SOUTH SAN FRANCISCO, Calif. , Feb.
SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc. , today announced a co-marketing relationship for scalable and simple-to-use tissue image analysis for Imaging Mass Cytometry ™ (IMC ™ ).
Gaining insights into inflammatory bowel disease through mass cytometry and Imaging Mass Cytometry analysis of the human mucosal immune system Research aimed at more precise treatments for IMIDs using existing therapies and identification of new targets for drug development SOUTH SAN FRANCISCO,
First commercially available, automated single-cell analysis application to enable co-detection of cellular protein and RNA expression using microfluidics technology SOUTH SAN FRANCISCO, Calif. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and
SOUTH SAN FRANCISCO, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 , after the close of
Mass cytometry services for pharmaceutical and biotechnology companies to accelerate development of new health insights SOUTH SAN FRANCISCO, Calif. and MONTREAL , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory
SOUTH SAN FRANCISCO, Calif. , Dec. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock.
